`Ranbaxy got USFDA nod with no data or fraudulent data`

India`s drug major Ranbaxy Laboratories used "fraudulent" data to get USFDA nod to sell its generic drugs, according to whistleblower Dinesh Thakur, who has also accused the drug-maker of faking test results.

Ranbaxy whistle-blower says drug maker faked data

An Indian origin whistle-blower, who exposed a massive fraud by the Indian pharmaceutical giant Ranbaxy, has accused the generic drug maker of faking test results for approval by the US drug regulator.

Ranbaxy gets CDSCO nod to sell malaria drug `SynriamTM`

Drug major Ranbaxy Laboratories Monday said it has received Indian drug regulator`s approval to market SynriamTM for treating malaria caused by Plasmodium vivax parasite.

Ranbaxy `systematically violated` good manufacturing practices: Whistleblower

Ranbaxy Laboratories "systemically violated" good manufacturing practices, says the whisteblower whose alert led to a US probe, a day after India`s top drugmaker agreed to pay a hefty USD 500 million to settle charges over its adulterated drugs.

Ranbaxy resumes supply of Atorvastatin tablets in US market

Drug major Ranbaxy Laboratories today said it has resumed the supply of Atorvastatin calcium tablets, a cholesterol lowering drug, in the US market.

Ranbaxy to sell generic anti-depression drug in US

The US arm of Indian drug major Ranbaxy Laboratories has entered into an in-licensing agreement with Alembic Pharmaceuticals Limited to exclusively market the generic version of Pfizer Inc.`s anti-depression drug Pristiq in the US.

Ranbaxy stops production of its generic Lipitor: USFDA

Ranbaxy Laboratories has stopped production of its generic version of cholesterol lowering drug Lipitor.

Ranbaxy launches generic diabetes drug in US

Ranbaxy Laboratories today said it has launched generic pioglitazone hydrochloride tablets used for treating diabetes in the American market.

Ranbaxy boosts presence in Africa with malaria drug

The arrival of the Synriam drug has come as a boon for many in a continent plagued by malaria.

India develops new synthetic anti-malaria drug

On the occasion of World Malaria Day on Wednesday, India has a good news for the world. The country has developed an indigenous new malaria drug which in turn will boost India’s pharmaceutical research.

Ranbaxy gets Health Canada nod for cholesterol lowering drug

Ranbaxy Laboratories today said it has received approval from the Health Canada to manufacture and market its generic RAN-Rosuvastatin tablets.

Ranbaxy gets USFDA approval for generic Lipitor

The US health regulator today granted approval to Ranbaxy Laboratories to produce generic version of cholesterol lowering drug Lipitor.

Ranbaxy buyout boosts Daiichi profit 10-fold

Daiichi Sankyo posted an April-June recurring profit of 70.1 billion yen (USD 808 million), up from 7.2 billion yen a year earlier.

7 Indian cos in Asia`s top 20 life science firms

Seven Indian companies are among
Asia`s top 20 publicly listed life science companies, says a
study.

Ranbaxy corrective actions have been inadequate: FDA

US Food and Drug
Administration (FDA) has said Ranbaxy is not taking adequate
corrective measures to meet regulatory requirements even after
receiving warning letters from it.

Ranbaxy to acquire bio-tech firm Biovel Lifesciensce

Ranbaxy Laboratories on Tuesday said it will acquire Bangalore-based Biovel Lifesciences for an undisclosed amount.

Ranbaxy to launch Daiichi Sankyo`s drug in Africa

The country`s largest drug maker by sales, Ranbaxy Laboratories, today said it would launch Olmesartan Medoxomil, an anti-hypertensive drug from parent company Daiichi Sankyo`s portfolio, in six African countries.

Ranbaxy to launch Daiichi Sankyo`s drug in Africa

Ranbaxy Laboratories will launch Olmesartan Medoxomil, an anti-hypertensive drug from parent company Daiichi Sankyo`s portfolio, in six African countries.

Ranbaxy ends JV with Japanese firm

Pharma company Ranbaxy Laboratories
today said it has exited from Japan-based joint venture
company--Nihon Pharmaceutical Industry.

Daiichi Sankyo to launch Ranbaxy`s drugs in Japan soon

Daiichi Sankyo, which has a
majority stake in Ranbaxy Laboratories, today said it is going
to launch some of Ranbaxy`s generic medicine in the Japanese
market soon.